Horizon Therapeutics has announced plans to expand its development and manufacturing facility in Waterford.
The company is adding a new drug substance biologics development as well as manufacturing capabilities.
They say it will result in the creation of approximately 350 jobs over time and it'll also add about 320,000 square feet to its current 44,000 square foot premises.
Horizon, who are based in the IDA Business Park near Whitfield, say a planning application for the facility has now been submitted.
Existing facility
This morning's announcement comes on the back of a smaller jobs announcement for their Waterford base back in May.
They purchased their existing facility there in June of 2021, for $65 million, with the understanding that adjacent IDA Ireland land was available for further manufacturing and development expansion.
The company works with Ireland's Health Products Regulatory Authority (HPRA) and the US Food and Drug Administration (FDA) to obtain licenses for sterile, fill-finish manufacturing and it's expected that the first medicine approved for release from the existing facility will be in 2023.
Both facilities are expected to be used for Horizon’s on market rare disease biologics as well as development-stage medicines.
Expansion
“As we grow as a global biotechnology company, it is important to continue to invest in our development and manufacturing capabilities to supplement our current network of contract manufacturing organizations to maintain flexibility over our production and supply,” said Tim Walbert, chairman, president and chief executive officer, Horizon.
“The planned expansion to add this drug substance facility is important to the long-term growth of our commercial and pipeline biologics as well as our commitment to Ireland.”
Horizon is a global biotechnology company dealing with the discovery, development and commercialization of medicines that address critical needs for people impacted by rare, autoimmune and severe inflammatory diseases.
For all your latest Waterford news and sport, click here.
